Third patient recovers two motor levels; three of six (50%) patients in AIS-A 10 million cell cohort have now recovered two motor levels on at least one side
FREMONT, Calif., June 13, 2017 /PRNewswire/ — Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company pioneering the field of regenerative medicine, today announced that new 9-month follow-up data from the AIS-A 10 million cell cohort in the company’s ongoing SCiStar Phase 1/2a clinical trial shows three of six (50%) patients have now recovered two levels of motor function and previously-announced improvements in arm, hand and finger function at 3-months and 6-months following administration of AST-OPC1 have been confirmed and further increased at 9-months.
Newly developed “glassy carbon” electrodes transmit more robust signals to restore motion in people with damaged spinal cords.
When people suffer spinal cord injuries and lose mobility in their limbs, it’s a neural signal processing problem. The brain can still send clear electrical impulses and the limbs can still receive them, but the signal gets lost in the damaged spinal cord.
Early clinical trial results announced offer new hope in regenerative medicine
A new therapy to treat spinal cord injuries in people who have lost all motor and sensory function below the injury site shows additional motor function improvement at 6-months and 9-months following treatment with 10 million AST-OPC1. The positive efficacy results from an ongoing research study were announced on Jan. 24 in a conference held by Asterias Biotherapeutics, Inc., the biotechnology company that manufactures AST-OPC1.
Researches in Germany studied whether time of surgery impacted neurological outcomes for patients with acute spinal cord injury, according to Journal of Therapeutics and Clinical Risk Management.
Specifically, they analyzed 51 spinal cord injury patients, aged an average of 43.4 years. The patients had acute spinal fractures from C2 to L3 or nonosseous lesions.
Monitoring upper-limb recovery after cervical spinal cord injury: insights beyond assessment scores.
Background: Pre-clinical investigations in animal models demonstrate that enhanced upper-limb (UL) activity during rehabilitation promotes motor recovery following spinal cord injury (SCI). Despite this, following SCI in humans, no commonly applied training protocols exist and therefore activity-based rehabilitative therapies (ABRT) vary in frequency, duration and intensity. Quantification of UL recovery is limited to subjective questionnaires or scattered measures of muscle function and movement tasks.
There have been many breakthroughs in treatment and care over the last 25 years, and even more improvements in accessibility. But there’s still a long way to go
On a warm summer night in 1978 , Robb Dunfield and two friends climbed up into a house under construction near Jericho Beach to get a better view of the pillowy tall ships floating in the harbour.
They stepped out onto a balcony where the railing had not yet been built. Instead, there was merely a board tapped into place with a nail at either end.
It gave way quickly and Dunfield, then an athletic 19-year-old with a zest for adventure, plunged 30 feet into the darkness. Down, down he went, crashing into an abyss. In those few moments, his life changed irrevocably.